Last reviewed · How we verify
standard statin monotherapy
Standard statin monotherapy works by inhibiting HMG-CoA reductase, a key enzyme in the cholesterol biosynthesis pathway.
Standard statin monotherapy works by inhibiting HMG-CoA reductase, a key enzyme in the cholesterol biosynthesis pathway. Used for Hypercholesterolemia, Atherosclerotic cardiovascular disease.
At a glance
| Generic name | standard statin monotherapy |
|---|---|
| Also known as | Atorvastatin or other equivalent types of statin |
| Sponsor | VA Office of Research and Development |
| Drug class | statin |
| Target | HMG-CoA reductase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
This inhibition leads to a decrease in the production of cholesterol in the liver, resulting in lower levels of low-density lipoprotein (LDL) cholesterol in the blood. Statins also have pleiotropic effects, including anti-inflammatory and antioxidant properties.
Approved indications
- Hypercholesterolemia
- Atherosclerotic cardiovascular disease
Common side effects
- Muscle pain
- Liver enzyme elevation
- Diabetes
Key clinical trials
- Focusing on the Menopausal Transition to Improve Mid-Life Women's Health (PHASE2, PHASE3)
- Cognitive Decline and Underlying Mechanisms in Symptomatic Intracranial Artery Stenosis Patients: A Cohort Study
- Cognitive Decline in Asymptomatic Intracranial Stenosis Patients: A 1-Year Follow-Up Study
- Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase II (PHASE3)
- Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase I (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- standard statin monotherapy CI brief — competitive landscape report
- standard statin monotherapy updates RSS · CI watch RSS
- VA Office of Research and Development portfolio CI